Alnylam Pharmaceuticals

Third Rock Ventures expands, strengthens team

Wednesday, May 15, 2013 09:38 AM

Third Rock Ventures, a venture capital firm focused on building healthcare companies, has expanded and strengthened its team with several appointments and role changes. These additions allow Third Rock to continue to support the launch of new companies focused on disruptive areas of science and medicine, the maturation and development of its current portfolio companies and the overall strategy and direction of the firm.

More... »

The Medicines Company, Alnylam develop RNAi therapeutics for hypercholesterolemia

Monday, February 4, 2013 09:51 AM

The Medicines Company, a global pharmaceutical company, and Alnylam Pharmaceuticals, an RNAi therapeutics company, have formed an exclusive global alliance for the development and commercialization of Alnylam's ALN-PCS RNAi therapeutic program targeting PCSK9 for the treatment of hypercholesterolemia.

More... »

Alnylam, Genzyme to develop and commercialize RNAi therapeutics in Asia

Monday, October 22, 2012 12:01 PM

Alnylam Pharmaceuticals, a biopharmaceutical company based in Cambridge, Mass., and Genzyme, a Sanofi company, have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

More... »

Alnylam and Monsanto form strategic alliance

Tuesday, August 28, 2012 02:51 PM

St. Louis-based Monsanto and Alnylam Pharmaceuticals of Cambridge, Mass., have formed a strategic alliance to advance biological technologies in the field of agriculture. The new alliance brings Alnylam's broad RNAi-based intellectual property (IP) and proprietary technologies to Monsanto's new BioDirect technology, which aims to deliver innovative biological solutions for farmers.

More... »

Alnylam to restructure, reduce workforce by 33%

Monday, January 23, 2012 12:25 PM

Alnylam Pharmaceuticals, an  RNAi therapeutics company, intends to implement a strategic corporate restructuring, including an approximate 33% reduction in its workforce, as it aligns its resources to focus on what it believes to be the company's highest value opportunities with accelerated clinical development plans.

More... »

Alnylamm, GSK collaborate in vaccine production

Thursday, November 3, 2011 01:13 PM

Alnylam Pharmaceuticals has formed a collaboration with GlaxoSmithKline focused on Alnylam's VaxiRNATM technology for certain GSK vaccine products, including influenza. VaxiRNA is a new RNAi technology for the enhanced production of viruses used in the manufacture of vaccine products. GSK is the first company to form a collaboration accessing this new platform.

More... »

Researchers use RNA technology to block inflammation

Tuesday, October 11, 2011 01:26 PM

Massachusetts General Hospital (MGH) researchers - along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals - have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication in Nature Biotechnology, the investigators describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage.

More... »